View in EDS HTML Full Text PDF Full Text

Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy.

Saved in:
Bibliographic Details
Title: Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy.
Authors: Ramos Perez, Jorge M.1 (AUTHOR), Patel, Keyur P.2 (AUTHOR), Loghavi, Sanam2 (AUTHOR), Garcia-Manero, Guillermo1 (AUTHOR), Borthakur, Gautam1 (AUTHOR), Jabbour, Elias1 (AUTHOR), Wierda, William1 (AUTHOR), Pierce, Sherry1 (AUTHOR), Brandt, Mark1 (AUTHOR), Kornblau, Steven1 (AUTHOR), Kadia, Tapan1 (AUTHOR), Daver, Naval1 (AUTHOR), DiNardo, Courtney D.1 (AUTHOR), Jain, Nitin1 (AUTHOR), Yilmaz, Musa1 (AUTHOR), Short, Nicholas1 (AUTHOR), Verstovsek, Srdan1 (AUTHOR), Ferrajoli, Alessandra1 (AUTHOR), Andreeff, Michael1 (AUTHOR), Konopleva, Marina1 (AUTHOR)
Source: Leukemia & Lymphoma. Mar2022, Vol. 63 Issue 3, p672-675. 4p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:10428194
DOI:10.1080/10428194.2021.1992757